The growth hormone-releasing peptide is a modified form of GHRH with an improved half-life
Bone 116 , 4246 (2018)
A more comprehensive understanding of the molecular networks governing ferroptosis in OA will facilitate the development of refined therapeutic strategies at multiple levels, potentially leading to improved structural and functional outcomes for patients
Kirchhof P, Benussi S, Kotecha D, et al
Wild type SOD1 can be misfolded by the aberrant translation, post-translational modification or oxidative modifications, due to the pathological conditions of the CNS environment, and produce toxic insoluble aggregates, as mutated SOD1 (Bosco et al., 2010
No evidence of long-term systemic, hormonal, or organ-specific toxicity has been reported in available preclinical data